ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
Biofil Chemicals & Pharmaceuticals shareholders approved the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director, despite him exceeding 75 years of age.
Biofil Chemicals and Pharmaceuticals Limited held its 41st Annual General Meeting on 23rd September 2026. Members transacted routine business, including adoption of financial statements and director re-appointments.
Biofil Chemicals is notifying shareholders with unregistered email addresses about how to access the Annual Report and AGM Notice, per Regulation 36(1)(b) compliance requirements.
Biofil Chemicals and Pharmaceuticals Limited has submitted its Integrated Annual Report for FY 2025-26. The 41st Annual General Meeting is scheduled for September 23, 2026.
Biofil Chemicals and Pharmaceuticals Limited will hold its 41st Annual General Meeting on September 23, 2026. The meeting will be conducted via video conferencing.
Biofil Chemicals announced the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director, subject to shareholder approval at the upcoming AGM.
Biofil Chemicals & Pharmaceuticals Ltd reported revenue from operations of ₹12.4 Cr (+93.8% YoY) and net profit of ₹0.1 Cr (-95.8% YoY) for Q1 FY27.
Biofil Chemicals & Pharmaceuticals Ltd has scheduled a board meeting for August 11, 2026, to consider and approve its unaudited financial results for Q1 FY27.
Biofil Chemicals & Pharmaceuticals Ltd reported revenue from operations of ₹7.6 Cr (-9.5% YoY) and net profit of ₹0.2 Cr (+0.0% YoY) for Q4 FY26.
Biofil Chemicals reported annual revenue of ₹28.40 Crore for FY26. The Board approved audited results with an unmodified auditor opinion during its May 2026 meeting.
Biofil Chemicals reported SEBI non-compliance regarding board composition and CS appointments, resulting in ₹0.08 Crore fines. The company has since normalized appointments and paid penalties.
Biofil Chemicals & Pharmaceuticals scheduled a board meeting for May 30, 2026. Directors will consider audited financial results for the quarter and year ended March 2026.
Biofil Chemicals & Pharmaceuticals Limited confirmed it does not qualify as a 'Large Corporate' as of March 31, 2026. The company reported outstanding borrowings of ₹0.02 Crore, falling below the SEBI framework threshold for mandatory debt issuance.